These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37467147)

  • 1. Government funding of fluorodeoxyglucose positron emission tomography (FDG-PET) in rare urological cancers: better data, better outcomes.
    Xu J; Al Saffar H; O'Brien J; Kelly B; Lawrentschuk N
    BJU Int; 2024 Feb; 133 Suppl 3():8-9. PubMed ID: 37467147
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on advances in molecular PET in urological oncology.
    Kitajima K; Yamamoto S; Fukushima K; Minamimoto R; Kamai T; Jadvar H
    Jpn J Radiol; 2016 Jul; 34(7):470-85. PubMed ID: 27222021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of PET/CT 18-FDG for the diagnosis and follow-up of urological, urothelial and kidney tumours.
    González-Ruiz de León C; García-Rodríguez J; Pérez-Castro N; Vigil-Díaz C; Pérez-Haro ML; Fernández-Gómez JM
    Actas Urol Esp (Engl Ed); 2019; 43(1):32-38. PubMed ID: 30100141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
    Lee JW; Nam SB; Kim SJ
    Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG in Urologic Malignancies.
    Høilund-Carlsen PF; Poulsen MH; Petersen H; Hess S; Lund L
    PET Clin; 2014 Oct; 9(4):457-68, vi. PubMed ID: 26050947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving role of positron emission tomography (PET) in urological malignancy.
    Mafeld S; Vasdev N; Patel A; Ali T; Lane T; Boustead G; Thorpe AC; Adshead JM; Haslam P
    BJU Int; 2015 Oct; 116(4):538-45. PubMed ID: 25410715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PET-FDG in metastases from urological malignancies].
    Labarthe P; Méjean A; Lebret T
    Prog Urol; 2008 Nov; 18 Suppl 7():S208-12. PubMed ID: 19070793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in urological cancers].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S80-7. PubMed ID: 12739339
    [No Abstract]   [Full Text] [Related]  

  • 9.
    Ederhy S; Devos P; Pinna B; Funck-Brentano E; Abbar B; Fenioux C; Cohen AA; Moslehi J; Bretagne M; Allenbach Y; Kharroubi D; Salem JE
    Arch Cardiovasc Dis; 2022 Feb; 115(2):114-116. PubMed ID: 35120869
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of
    Mori M; Fujioka T; Ichikawa R; Inomata R; Katsuta L; Yashima Y; Yamaga E; Tsuchiya J; Hayashi K; Kumaki Y; Oda G; Nakagawa T; Onishi I; Kubota K; Tateishi U
    Tomography; 2022 Oct; 8(5):2533-2546. PubMed ID: 36287810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron Emission Tomography/Computed Tomography Transformation of Oncology: Melanoma and Skin Malignancies.
    Lee ST; Kovaleva N; Senko C; Kee D; Scott AM
    PET Clin; 2024 Apr; 19(2):231-248. PubMed ID: 38233284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic Malignancies.
    Gnanasegaran G; Agrawal K; Wan S
    PET Clin; 2022 Jul; 17(3):369-388. PubMed ID: 35717098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET/CT: Radiation Therapy Planning in Head and Neck Cancer.
    Eraj S; Sher DJ
    PET Clin; 2022 Apr; 17(2):297-305. PubMed ID: 35256302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First [18F]-FDG-PET/CT images of a patient infected with Monkeypox.
    Manta R; Muteganya R; Gohimont N; Heymans B; Ene D
    Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):966-967. PubMed ID: 36334107
    [No Abstract]   [Full Text] [Related]  

  • 15. The lytic skeletal lesions: A rare presentation of carcinoma prostate on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
    Pande S; Mhatre N; Dhal I
    J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S939-S942. PubMed ID: 38384085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma.
    Kobayashi M; Tanaka H; Tateishi U; Numao N; Yonese J; Ito M; Koga F; Fukushima H; Uehara S; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
    Int J Urol; 2019 Aug; 26(8):820-826. PubMed ID: 31140215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On Semiquantitative Methods for Assessing Vascular
    Laffon E; Marthan R
    J Nucl Med; 2022 Feb; 63(2):325-326. PubMed ID: 34475239
    [No Abstract]   [Full Text] [Related]  

  • 18. What is this image? 2022 image 2 result: Right atrial angiosarcoma detected with
    Liang HX; Yang YL; Ren JY; Xie Z; Zhang Q; Liu ET; Wang SX
    J Nucl Cardiol; 2022 Oct; 29(5):2071-2076. PubMed ID: 36066792
    [No Abstract]   [Full Text] [Related]  

  • 19. [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].
    Machtens S; Boerner AR; Hofmann M; Knapp WH; Jonas U
    Urologe A; 2004 Nov; 43(11):1397-409. PubMed ID: 15502907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers.
    Avril N; Dambha F; Murray I; Shamash J; Powles T; Sahdev A
    Int J Urol; 2010 Jun; 17(6):501-11. PubMed ID: 20370848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.